Apellis Pharmaceuticals, Inc. Common Stock (APLS) is a publicly traded Healthcare sector company. As of May 21, 2026, APLS trades at $41.03 with a market cap of $5.25B and a P/E ratio of -25.64. APLS moved -0.04% today. Year to date, APLS is +64.32%; over the trailing twelve months it is +137.44%. Its 52-week range spans $16.10 to $41.14. Analyst consensus is neutral with an average price target of $39.50. Rallies surfaces APLS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Biogen Finalizes $5.3B Acquisition of Apellis, Gains $689M Drugs: Biogen completed its $5.3 billion acquisition of Apellis Pharmaceuticals on May 14, acquiring two complement-targeting drugs that generated $689 million in net revenue in 2025. Shareholders received $41 per share plus CVRs worth up to $4 tied to SYFOVRE revenue milestones through 2031 for a potential $582 million payout.
| Metric | Value |
|---|---|
| Price | $41.03 |
| Market Cap | $5.25B |
| P/E Ratio | -25.64 |
| EPS | $-1.60 |
| Dividend Yield | 0.00% |
| 52-Week High | $41.14 |
| 52-Week Low | $16.10 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $781.37M |
| Net Income | $-197.88M |
| Gross Margin | 0.00% |
18 analysts cover APLS: 0 strong buy, 2 buy, 16 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $39.50.